Welcome to our dedicated page for CoreWeave SEC filings (Ticker: CRWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CoreWeave, Inc. filings document the regulatory record for an AI cloud infrastructure company listed on Nasdaq with Class A common stock. The company’s 8-K reports cover operating results, customer cloud-capacity agreements, private placements of equity securities, senior notes, credit facilities, and related guarantees or collateral arrangements.
Proxy materials disclose annual meeting matters, stockholder voting items, board governance, executive compensation, and equity-award information. Capital-structure filings describe senior unsecured notes due 2031, subsidiary guarantees, private placement registration rights, and debt facilities used to finance GPU servers and related infrastructure for customer contracts.
CRWV has a planned sale notice under Rule 144 for 281,250 shares of common stock, to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on or around 02/04/2026. The filing lists an aggregate market value of 25329375.00 for these shares and notes that 386401201 common shares were outstanding, with the securities listed on NASDAQ.
The 281,250 shares to be sold were acquired as Founders Shares from the issuer on 12/27/2023, in the same amount, with payment dated 12/27/2023 and nature of payment marked as N/A. The notice also details multiple recent sales of the issuer’s common stock over the past three months by entities and persons such as WEST CLAY CAPITAL LLC, BRIAN VENTURO, YOLO APV TRUST, YOLO ECV TRUST, and a Non-Affiliate Donee, including individual transactions of up to 281250 shares and gross proceeds as high as 25810087.50, some executed under 10b5-1 trading plans.
CareView Communications (symbol CRWV) filed a notice of proposed insider share sales. The filing covers 8,335 common shares with an aggregate market value of $776,738.65, to be sold through Morgan Stanley Smith Barney on the Nasdaq market. The issuer reports 386,401,201 common shares outstanding. The 8,335 shares were originally acquired on 02/25/2019 as founder shares from the issuer.
The document also lists extensive Rule 10b5-1 programmed sales in the past three months by Brannin McBee, related trusts and GRATs, and a non-affiliate donee. Individual transactions include a non-affiliate donee sale of 257,733 common shares for $19,592,527.61, alongside multiple other large 10b5-1 sales of CRWV common stock.
CRWV reports a planned Rule 144 sale of 25,000 common shares, with an aggregate market value of $2,329,750.00. These shares are founder shares acquired on February 25, 2019 directly from the issuer, with full payment made that same day.
The notice states that 386,401,201 common shares were outstanding, and the proposed sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ exchange around February 2, 2026. The filing also lists extensive recent sales under Rule 10b5-1 trading plans by Brannin McBee-related trusts and entities, including a non-affiliate donee sale of 257,733 shares for $19,592,527.61 during the prior three months.
This Form 144 notice discloses a planned sale of 1,000 shares of common stock of CRWV through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an approximate sale date of 02/02/2026. The shares to be sold were acquired as founders shares from the issuer on 02/25/2019.
The filing also lists extensive Rule 10b5-1 sales of CRWV common stock during the past three months by Brannin J. McBee, related trusts and GRATs, and a non-affiliate donee. Examples include 102835 common shares sold on 01/26/2026 for $10432309.16, and 257733 shares sold on 12/01/2025 for $19592527.61. The person on whose behalf the shares are sold represents that they do not know any undisclosed material adverse information about the issuer’s current or prospective operations.
A shareholder filed a Form 144 notice to sell 1,000 shares of common stock through Morgan Stanley Smith Barney LLC, targeting an approximate sale date of 02/02/2026 on NASDAQ with an aggregate market value of $93,190.
The notice states that these 1,000 shares were acquired on 02/25/2019 as founder shares from the issuer, and indicates 386,401,201 shares of this class outstanding. This is a planned resale by an existing holder, not a new share issuance.
The filing also lists extensive Rule 10b5‑1 plan transactions over the past three months by Brannin McBee, multiple Canis Major and Canis Minor trusts and related entities, detailing repeated blocks of common-share sales and their gross proceeds.
A shareholder in CRWV has filed a notice of intent to sell 3,000 shares of common stock, with an aggregate market value of $279,570.00. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ, with an approximate sale date of 02/02/2026.
The filing notes that these shares were acquired as founders shares on 02/25/2019. It also lists extensive prior sales of the issuer’s common stock over the past three months by various trusts and entities at the same Livingston, New Jersey address, providing context on recent selling activity.
An affiliated holder of CRWV has filed a notice of proposed sale of 102,830 common shares, to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $9,582,727.70. These shares are part of founders’ shares originally acquired from the issuer on 02/25/2019. The filing notes that 386,401,201 common shares were outstanding when the notice was prepared. It also lists extensive recent Rule 10b5‑1 plan sales of CRWV common stock over the prior three months by Brannin McBee, multiple related trusts and entities, and a non‑affiliate donee, each with specified share amounts and gross proceeds.
A Rule 144 notice discloses a planned sale of 500 common shares of the issuer through Morgan Stanley Smith Barney LLC, with an aggregate market value of $46,595.00. The shares are listed on NASDAQ and the approximate sale date is 02/02/2026.
The seller acquired these 500 shares as founders shares from the issuer on 02/25/2019, with payment also dated 02/25/2019. The filing also lists extensive Rule 10b5-1 plan sales of common stock over the prior three months by various trusts and a non-affiliate donee, including one non-affiliate sale of 257,733 shares for $19,592,527.61.
CoreWeave, Inc. CEO and President Michael N. Intrator reported multiple sales of Class A common stock on January 28, 2026, executed under a Rule 10b5-1 trading plan adopted on May 23, 2025. Direct transactions included several small block sales at weighted average prices between about $103.61 and $113.87, leaving him with 5,796,323 Class A shares held directly.
Separately, Omnadora Capital LLC, an entity whose manager is controlled by Intrator, converted 50,000 shares of Class B common stock into Class A and then reported multiple sales of Class A shares at weighted average prices from about $103.61 to $113.87, reducing Omnadora’s Class A position to zero. Intrator also reports substantial Class B holdings through various family trusts and his spouse, each disclosed with detailed ownership footnotes.
CoreWeave, Inc. Principal Accounting Officer Jeff Baker reported an RSU vesting and related share sale. On January 29, 2026, 12,500 restricted stock units were converted into 12,500 shares of Class A Common Stock at an exercise price of $0.00 per share.
On the same date, Baker sold 5,143 Class A Common shares at a weighted average price of $103.7837 per share to cover tax withholding obligations from the RSU vesting. After these transactions, Baker directly owned 39,304 Class A Common shares and 125,000 restricted stock units.